More Than Weight Loss? GLP-1s and Cardiovascular Risk

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the Surpass CVOT trial, which evaluates the cardiovascular outcomes of Monjaro compared to Dulaglutide (Trulicity). They delve into the significance of the trial, the implications of the results, and the potential benefits of Monjaro for patients with type 2 diabetes and cardiovascular risks. The conversation highlights the importance of understanding cardiovascular outcome trials and the evolving landscape of diabetes medications.

Takeaways: 

The Surpass CVOT trial compares Mounjaro to Dulaglutide.

Dulaglutide has shown cardiovascular benefits in previous trials.

The trial results indicate Monjaro is at least not inferior to Dulaglutide.

There is a trend towards better cardiovascular outcomes with Mounjaro.

Weight loss and glycemic control are significant benefits of Mounjaro.

The trial did not include a placebo, but used a putative analysis.

The results are reassuring for patients at high cardiovascular risk.

The conversation emphasizes the importance of comprehensive treatment for metabolic diseases.

The hosts express enthusiasm for the potential of Mounjaro.

Future discussions will delve deeper into the trial's findings.

 

 

 

 

 

 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.